IL4 and neoplasm: GNP10 also enhanced the ability of HEp-2-treated DCs to stimulate the production of IL-4 by CD3+T cells (Figure 6D), suggesting that HEp-2/GNP10-treated DCs could have an impaired anti-tumor activity.